Michael Köhler and Stephan Weber nominated for the Supervisory Board of Redcare Pharmacy.
|
EQS-News: Redcare Pharmacy N.V.
/ Key word(s): AGM/EGM
Michael Köhler and Stephan Weber nominated for the Supervisory Board of Redcare Pharmacy. Sevenum, 2 April 2025. At Redcare Pharmacy’s upcoming Annual General Meeting (AGM) on 15 May 2025, changes to the composition of the Supervisory Board will be on the agenda. Redcare Pharmacy nominates the company’s founders and former board members Michael Köhler and Stephan Weber to succeed Frank Köhler and Henriette Peucker, who have decided to leave at the end of their current terms. Björn Söder, Chairman of the Supervisory Board, comments: "I would like to express my sincere gratitude to Henriette and Frank. Their expertise and dedication have played a key role in driving Redcare's success. As chair of the Nomination Committee, Henriette was central to shaping the current composition of the Managing Board. During her tenure, an external CEO search and the internal succession of the CCO and CIO were completed. Frank’s long-standing tenure, along with his profound financial expertise and business acumen, has been crucial for the development of Redcare from a start-up to Europe’s leading online pharmacy. At the same time, I am excited to welcome back Michael and Stephan – two individuals who embody true entrepreneurial spirit and bring considerable industry knowledge to the Supervisory Board. With his proven track record in the scaling of e-commerce initiatives, Stephan will be an ideal addition to help drive the company’s next growth phase. Coupled with Michael's strategic mindset as well as his extensive Rx online pharmacy and pharma industry expertise, both new members will be invaluable assets as we continue to advance our long-term strategy." Alongside the nomination of Michael Köhler and Stephan Weber, it is proposed to re-appoint Jérôme Cochet for a term of one year. Subject to the approval of the Annual General Meeting, the Supervisory Board will consist of Björn Söder (Chairman), Jaska de Bakker (Deputy Chairwoman), Jérôme Cochet, Michael Köhler and Stephan Weber. The convocation of the AGM has been published on the company's website today.
Investor Relations Contact: Monica Ambrosi (Associate Director, Investor Relations) investors@redcare-pharmacy.com
Press Contact: Sven Schirmer (Director, Corporate Communications)
About Redcare Pharmacy. Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven. As the one-stop pharmacy of the future, Redcare Pharmacy offers 12.5 million active customers a wide range of more than 250,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management. Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.
02.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2110240 |
| End of News | EQS News Service |
|
|
2110240 02.04.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.